ThomasG.MartinMD

Hematology • San Francisco, CA

Professor, Medicine, UCSF School of Medicine

Join to view full profile

Dr. Martin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Martin's full profile

Already have an account?

Office
505 Parnassus Ave
San Francisco, CA 94143
Phone+1 415-476-1000

Fax+1 925-838-6177
Is this information wrong?

Education & Training

University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 1993 - 1996
Los Angeles County-Harbor-UCLA Medical CenterResidency, Internal Medicine, 1989 - 1992
Uconn School Of MedicineClass of 1989

Certifications & Licensure

CA State Medical License 1991 - 2024
UT State Medical License 2013 - 2018
MO State Medical License 2012 - 2017
WA State Medical License 1996 - 2017
NE State Medical License 2015 - 2016
ME State Medical License 2014 - 2014
TX State Medical License 1999 - 2002
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer Start of enrollment: 1999 Jan 01
Completed
Not Applicable
Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Start of enrollment: 2002 Jan 01
Withdrawn
Phase 2
Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer Start of enrollment: 2004 Sep 01
Completed
Phase 1
Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer Start of enrollment: 2002 Oct 01
Completed
Phase 1
Unrelated Stem Cell Transplantation for Adults With Hematopoietic Disorders Start of enrollment: 1999 Jan 01
Completed
Filgrastim-Mobilized Peripheral Blood Stem Cells for Allogeneic Transplantation With Unrelated Donors Start of enrollment: 2005 Aug 01
Completed
Pilot Study of Reduced-Intensity Umbilical Cord Blood Transplantation in Adult Patients Wtih Advanced Hematopoietic Malignancies Start of enrollment: 2004 Aug 01
Terminated
Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies Start of enrollment: 2002 Oct 01
Terminated
Not Applicable
Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT Start of enrollment: 2002 Nov 01
Completed
Phase 2
A Phase I/II Study of Liposomal Doxorubicin (Doxil)/Melphalan/Bortezomib (Velcade) in Relapsed/Refractory Multiple Myeloma Start of enrollment: 2004 Oct 01
Withdrawn
Phase 1, Phase 2
Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma Start of enrollment: 2004 Oct 28
Terminated
Phase 1, Phase 2
Health-Related Quality of Life (QOL), Physical and Respiratory Function in Patients With Myeloma Affecting the Spine Start of enrollment: 2010 Feb 01
Completed
Targeted, Dose-Escalation Busulfan-Etoposide as Prep Regimen Start of enrollment: 2009 Nov 01
Completed
Phase 1
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) Start of enrollment: 2011 Oct 01
Recruiting
Join now to see all

Publications & Presentations

PubMed

1 citations
CD46-Targeted Theranostics for PET and 225Ac-Radiopharmaceutical Therapy of Multiple Myeloma.
Wadhwa, A., Wang, S., Patiño-Escobar, B., Bidkar, A., Bobba, K., Chan, E., Meher, N., Bidlingmaier, S., Su, Y., Dhrona, S., Geng, H., Sarin, V., VanBrocklin, H., Wilso...> ;Clinical Cancer Research. 2024 Mar 1
Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.
Thomas Martin, Meletios-Athanasios Dimopoulos, Joseph Mikhael, Kwee Yong, Marcelo Capra, Thierry Facon, Roman Hajek, Ivan Špička, Ross Baker, Kihyun Kim, Gracia Martin...> ;Blood Cancer Journal. 2023 Sep 27
2 citations
Randomized phase 2 study of digital life coaching during transplantation for myeloma.
Rahul Banerjee, Chiung-Yu Huang, Chloe Ryan, Albert Lee, Kelly J Brassil, Jasmine Moore, Shagun Arora, Alfred Chung, Sandy W Wong, Jeffrey Wolf, Thomas Martin, Anand D...> ;Bone Marrow Transplantation. 2023 Dec 1
Association of geriatric measures and global frailty with cognitive decline after allogeneic hematopoietic cell transplantation in older adults.
Li-Wen Huang, Ying Shi, Charalambos Andreadis, Aaron C Logan, Gabriel N Mannis, Catherine C Smith, Karin M L Gaensler, Thomas G Martin, Lloyd E Damon, W John Boscardin...> ;Journal of Geriatric Oncology. 2023 Nov 1
1 citations
Evaluation of venous thromboembolism prophylaxis protocol in hematopoietic cell transplant patients.
Angela Lee, Corinne Badgley, Mimi Lo, Marisela Tan Banez, Larissa Graff, Lloyd Damon, Thomas Martin, John Dzundza, Melisa Wong, Rebecca Olin> ;Bone Marrow Transplantation. 2023 Nov 1
2 citations
Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study.
Myo Htut, Binod Dhakal, Adam D Cohen, Thomas Martin, Jesus G Berdeja, Saad Z Usmani, Mounzer Agha, Carolyn C Jackson, Deepu Madduri, William Deraedt, Enrique Zudaire, ...> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Dec 1
6 citations
Isatuximab plus carfilzomib and dexamethasone in patients with earlylate relapsed multiple myeloma: IKEMA subgroup analysis.
Thierry Facon, Philippe Moreau, Ross Baker, Chang-Ki Min, Xavier Leleu, Mohamad Mohty, Lionel Karlin, Nicole M Armstrong, Christina Tekle, Sandrine Schwab, Marie-Laure...> ;Haematologica. 2024 Feb 1
2 citations
Cilta-cel, a BCMA-targeting CAR-T therapy for heavily pretreated patients with relapsed/refractory multiple myeloma.
Thomas G Martin, Deepu Madduri, Lida Pacaud, Saad Z Usmani> ;Future Oncology. 2023 Nov 1
Plain language summary of the CARTITUDE-1 study of ciltacabtagene autoleucel for the treatment of people with relapsed or refractory multiple myeloma.
Jesus G Berdeja, Adam D Cohen, Thomas Martin, Deepu Madduri, Lida Pacaud, Sundar Jagannath> ;Future Oncology. 2023 Jun 1
Extrapolation of Survival Data Using a Bayesian Approach: A Case Study Leveraging External Data from Cilta-Cel Therapy in Multiple Myeloma.
Stephen Palmer, Yi Lin, Thomas G Martin, Sundar Jagannath, Andrzej Jakubowiak, Saad Z Usmani, Nasuh Buyukkaramikli, Hilary Phelps, Rafal Slowik, Feng Pan, Satish Vallu...> ;Oncology and Therapy. 2023 Sep 1
Cytomegalovirus seropositivity is associated with improved responses to CD38 monoclonal antibody therapies in multiple myeloma: A single-centre retrospective study.
Alex Y Ge, Chiung-Yu Huang, Rahul Banerjee, Jennifer Knoche, Alfred Chung, Shagun Arora, Jeffrey Wolf, Sandy W Wong, Arun P Wiita, Nina Shah, Martin, T.> ;British Journal of Haematology. 2023 Jun 1
Intensity of Cyclophosphamide-Based Bridging Therapy Before Chimeric Antigen Receptor T Cell Therapy in Myeloma.
Aneeqa Zafar, Chiung-Yu Huang, Mimi Lo, Shagun Arora, Alfred Chung, Sandy W Wong, Jeffrey Wolf, Thomas G Martin, Nina Shah, Rahul Banerjee> ;Transplantation and Cellular Therapy. 2023 Aug 1
12 citations
Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.
Thomas Martin, Meletios-Athanasios Dimopoulos, Joseph Mikhael, Kwee Yong, Marcelo Capra, Thierry Facon, Roman Hajek, Ivan Špička, Ross Baker, Kihyun Kim, Gracia Martin...> ;Blood Cancer Journal. 2023 May 9
Significance of the pee-value: relevance of 24-hour urine studies for patients with myeloma.
Kelsey H Natsuhara, Chiung-Yu Huang, Jennifer Knoche, Shagun Arora, Alfred Chung, Thomas Martin, Jeffrey Wolf, Sandy W Wong, Nina Shah, Rahul Banerjee> ;Leukemia & Lymphoma. 2023 Jun 1
5 citations
Safety and Efficacy of BCMA CAR-T Cell Therapy in Older Patients With Multiple Myeloma.
Kevin R Reyes, Chiung-Yu Huang, Mimi Lo, Shagun Arora, Alfred Chung, Sandy W Wong, Jeffrey Wolf, Rebecca L Olin, Thomas Martin, Nina Shah, Rahul Banerjee> ;Transplantation and Cellular Therapy. 2023 Jun 1
1 citations
Daratumumab Plus Bortezomib and Dexamethasone in Newly Diagnosed Systemic Light Chain Amyloidosis.
Vanessa E Kennedy, Kelsey Natsuhara, Sireesha A Maringanti, Nina D Shah, Shagun Arora, Jeffrey Wolf, Thomas G Martin, Mandar A Aras, Alfred Chung, Sandy W Wong> ;Current Problems in Cancer. 2023 Jun 1
7 citations
Adjusted comparison of outcomes between patients from CARTITUDE-1multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and ant...
Maria-Victoria Mateos, Katja Weisel, Thomas Martin, Jesús G Berdeja, Andrzej Jakubowiak, A Keith Stewart, Sundar Jagannath, Yi Lin, Joris Diels, Francesca Ghilotti, Pu...> ;Haematologica. 2023 Aug 1
11 citations
Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis.
Ivan Spicka, Philippe Moreau, Thomas G Martin, Thierry Facon, Gracia Martinez, Albert Oriol, Youngil Koh, Andrew Lim, Gabor Mikala, Laura Rosiñol, Münci Yağci, Michele...> ;European Journal of Haematology. 2022 Nov 1
10 citations
Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study.
Thomas Martin, Yi Lin, Mounzer Agha, Adam D Cohen, Myo Htut, A Keith Stewart, Parameswaran Hari, Jesus G Berdeja, Saad Z Usmani, Tzu-Min Yeh, Yunsi Olyslager, Jenna D ...> ;The Lancet. Haematology. 2022 Dec 1
20 citations
Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes.
Xavier Leleu, Thomas Martin, Katja Weisel, Fredrik Schjesvold, Shinsuke Iida, Fabio Malavasi, Salomon Manier, Chang-Ki Min, Enrique M Ocio, Charlotte Pawlyn, Aurore Pe...> ;Annals of Hematology. 2022 Oct 1
2 citations
Evaluation of isatuximab in patients with soft-tissue plasmacytomas: An analysis from ICARIA-MM and IKEMA.
Meral Beksac, Ivan Spicka, Roman Hajek, Sara Bringhen, Tomas Jelínek, Thomas Martin, Gabor Mikala, Philippe Moreau, Argiris Symeonidis, Andreea M Rawlings, Helgi van d...> ;Leukemia Research. 2022 Nov 1
3 citations
Antibody and T-cell responses by ultra-deep T-cell receptor immunosequencing after COVID-19 vaccination in patients with plasma cell dyscrasias.
Alfred Chung, Barbara Banbury, Marissa Vignali, Chiung-Yu Huang, Sireesha Asoori, Rachel Johnson, Theodore Kurtz, Shagun Arora, Sandy W Wong, Nina Shah, Thomas G Marti...> ;British Journal of Haematology. 2022 Nov 1
1 citations
Patterns and Predictors of Functional Decline after Allogeneic Hematopoietic Cell Transplantation in Older Adults.
Li-Wen Huang, Ying Sheng, Charalambos Andreadis, Aaron C Logan, Gabriel N Mannis, Catherine C Smith, Karin M L Gaensler, Thomas G Martin, Lloyd E Damon, Chiung-Yu Huan...> ;Transplantation and Cellular Therapy. 2022 Jun 1
8 citations
Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis.
Meletios A Dimopoulos, Philippe Moreau, Bradley Augustson, Nelson Castro, Tomas Pika, Sosana Delimpasi, Javier De la Rubia, Angelo Maiolino, Tony Reiman, Joaquin Marti...> ;American Journal of Hematology. 2023 Jan 1
41 citations
Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group.
Noopur S Raje, Elias Anaissie, Shaji K Kumar, Sagar Lonial, Thomas Martin, Morie A Gertz, Amrita Krishnan, Parameswaran Hari, Heinz Ludwig, Elizabeth O'Donnell, Andrew...> ;The Lancet. Haematology. 2022 Feb 1
Join now to see all

Lectures

Approaches To Achieve the Best Possible Outcomes in Myeloma
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Managing Multiple Myeloma: What's Next?
60th American Society of Hematology Annual Meeting - 11/30/2018

Press Mentions

FDA Approves New CAR T Cancer Therapy for Form of Multiple MyelomaFebruary 28th, 2022
New Data from CARTITUDE-1 Study Show Continued Deep and Durable Responses of Ciltacabtagene Autoleucel (Cilta-Cel) in Treatment of Heavily Pre-Treated Patients with Multiple MyelomaDecember 12th, 2021

Hospital Affiliations

UCSF Medical CenterSan Francisco, California
Zuckerberg San Francisco General Hospital and Trauma CenterSan Francisco, California

ThomasG.MartinMD

Dr. Martin is on Doximity

Education & Training

Certifications & Licensure

Awards, Honors, & Recognition

Clinical Trials

Publications & Presentations

Press Mentions

Hospital Affiliations

Viewing the full profile is available to verified healthcare professionals only.